We reasoned that an effective and safe approach for DS therapy would require a neuron-specific promoter that drives NaV1.1 expression in both inhibitory and excitatory neurons in the hippocampus, and moderate expression in nonhippocampal glutamatergic neurons that project to the injection site. This evidence concerns the gene SCN1A and Dravet syndrome.